Leukemia & Lymphoma最新文献_第2页

Clinical outcomes of adults with PAX5-mutated or rearranged B-cell acute lymphoblastic leukemia. pax5突变或重排的成人b细胞急性淋巴细胞白血病的临床结果

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-01 DOI: 10.1080/10428194.2026.2740988

Rick Y Lin, Jose Tinajero, Zhaohui Gu, Vaibhav Agrawal, Hoda Pourhassan, Tamer Othman, Paul Koller, Anthony Stein, Guido Marcucci, Vinod Pullarkat, Ibrahim Aldoss

{"title":"Clinical outcomes of adults with PAX5-mutated or rearranged B-cell acute lymphoblastic leukemia.","authors":"Rick Y Lin, Jose Tinajero, Zhaohui Gu, Vaibhav Agrawal, Hoda Pourhassan, Tamer Othman, Paul Koller, Anthony Stein, Guido Marcucci, Vinod Pullarkat, Ibrahim Aldoss","doi":"10.1080/10428194.2026.2740988","DOIUrl":"https://doi.org/10.1080/10428194.2026.2740988","url":null,"abstract":"PAX5 is one of the most frequently altered genes in B‑cell acute lymphoblastic leukemia (B‑ALL), yet the impact of its specific alterations on adult outcomes remains incompletely defined. We conducted a retrospective analysis of 42 adults with PAX5-mutated or rearranged B-ALL, including PAX5 P80R mutations (n = 6), PAX5 fusions (n = 11), and other PAX5 mutations (n = 25). The median age was 41 years and 83% were Hispanic. Complete remission and minimal residual disease negative rates after induction were 78.6% and 53.8%, respectively. Median overall survival (OS) was 30.1, 53.7, and not reached (NR) months for P80R, fusions, and other PAX5 mutations, respectively. Median relapse-free survival was 12.1, NR, and 88.5 months for the same groups. CDKN2A/B co-deletions trended toward inferior OS (HR 2.69, p = 0.105). In multivariate analysis, PAX5 fusions were independently associated with inferior OS (HR 7.79, p = 0.018). PAX5‑altered ALL represents a heterogeneous group with diverse mutations that may influence prognosis.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of three-drug induction-based MASPORE 2003 chemotherapy protocol in standard- and intermediate-risk pediatric acute lymphoblastic leukemia: a decade-long single-center experience from India. 基于三种药物诱导的MASPORE 2003化疗方案治疗标准和中危儿童急性淋巴细胞白血病的疗效和安全性：来自印度的长达十年的单中心经验。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-01 DOI: 10.1080/10428194.2026.2739354

Surabhi Pokhariyal, Sohini Chakraborty, Sunisha Arora, Parminder Pal Singh, Vaibhav Chadha, Satyendra Batra, Rahul Bhargava, Vikas Dua

引用次数: 0

Venetoclax consolidation deepens response and enables measurable residual disease-guided finite therapy in BTK inhibitor-treated chronic lymphocytic leukemia. Venetoclax巩固加深了BTK抑制剂治疗的慢性淋巴细胞白血病的反应，并使可测量的残留疾病引导有限治疗成为可能。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-01 DOI: 10.1080/10428194.2026.2741763

Ahmad Alhuraiji, Salem Alshemmari, Abdulaziz Hamadah, Nitin Jain

{"title":"Venetoclax consolidation deepens response and enables measurable residual disease-guided finite therapy in BTK inhibitor-treated chronic lymphocytic leukemia.","authors":"Ahmad Alhuraiji, Salem Alshemmari, Abdulaziz Hamadah, Nitin Jain","doi":"10.1080/10428194.2026.2741763","DOIUrl":"https://doi.org/10.1080/10428194.2026.2741763","url":null,"abstract":"Continuous Bruton tyrosine kinase inhibitor (BTKi) therapy is effective in chronic lymphocytic leukemia (CLL) but rarely eradicates measurable residual disease (MRD) and commits patients to indefinite treatment. In this single-center, real-world series, venetoclax was added as consolidation in 8 patients on continuous BTKi with adverse events and persistent peripheral-blood MRD. Patients were predominantly high-risk (6 of 8 IGHV-unmutated; 1 TP53-mutated) and had received BTKi for a median of 35 months. MRD was measured by flow cytometry (sensitivity 10-5). At a median follow-up of 12 months, all had MRD reductions; 4 of 6 evaluable patients (66%) achieved undetectable MRD (<10-5), the 2 remaining on therapy being non-evaluable. Six completed the 12-month course and stopped all therapy; 1 later relapsed. Treatment was well tolerated: grade 4 neutropenia in 2 patients, no tumor lysis syndrome, and no treatment-related deaths. Venetoclax consolidation is feasible, deepens response, and enables MRD-guided finite therapy in BTKi-treated CLL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-6"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterizing the landscape of hospitalizations for multiple myeloma in Spain: a retrospective analysis (2016-2023). 西班牙多发性骨髓瘤住院的特点：一项回顾性分析（2016-2023）。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-30 DOI: 10.1080/10428194.2026.2732485

Ane Brieva-Lopez, Maria Ordoñez-Garcia, Mariana Cerrato-Salas, Pavel Manuel Acevedo-Pérez, Juan Sastre-Ortega, Maria Ángeles Andreu-Costa, Rafael Garcia-Carretero

{"title":"Characterizing the landscape of hospitalizations for multiple myeloma in Spain: a retrospective analysis (2016-2023).","authors":"Ane Brieva-Lopez, Maria Ordoñez-Garcia, Mariana Cerrato-Salas, Pavel Manuel Acevedo-Pérez, Juan Sastre-Ortega, Maria Ángeles Andreu-Costa, Rafael Garcia-Carretero","doi":"10.1080/10428194.2026.2732485","DOIUrl":"https://doi.org/10.1080/10428194.2026.2732485","url":null,"abstract":"Multiple myeloma (MM) is a chronic hematological malignancy associated with substantial morbidity and healthcare utilization. We conducted a retrospective population-based study using the Spanish Minimum Basic Data Set to analyze MM-related hospitalizations in Spain. All hospitalizations with a diagnosis of MM during the study period were included. Demographic characteristics, comorbidities, complications, and outcomes were assessed, and temporal trends were evaluated using quasi-Poisson regression models. A total of 107,496 hospitalizations involving 43,383 unique patients were analyzed. Hospitalization rates increased significantly over the study period, from 25.1 to 34.6 per 100,000 population (p < 0.001). Median patient age at hospitalization was 73 years, and 47% were women. In-hospital mortality was 11%, decreasing from 13% in 2016 to 9.6% in 2023 despite an increasing comorbidity burden. Mortality increased with age, and marked regional variability was observed. These findings indicate a growing healthcare burden but improved survival, likely reflecting advances in MM treatment and supportive care.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic accuracy and clinical usefulness of lung ultrasound in onco hematological patients with neutropenic fever. 肺超声诊断嗜中性粒细胞减少热肿瘤血液病的准确性及临床应用价值。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-23 DOI: 10.1080/10428194.2026.2727810

Carolina Secreto, Veronica Peri, Jessica Gill, Matteo Olivi, Simone Ragaini, Eloise Beggiato, Ernesta Audisio, Benedetto Bruno, Roberto Freilone, Alessandro Busca, Andrea Costamagna, Emanuele Pivetta

{"title":"Diagnostic accuracy and clinical usefulness of lung ultrasound in onco hematological patients with neutropenic fever.","authors":"Carolina Secreto, Veronica Peri, Jessica Gill, Matteo Olivi, Simone Ragaini, Eloise Beggiato, Ernesta Audisio, Benedetto Bruno, Roberto Freilone, Alessandro Busca, Andrea Costamagna, Emanuele Pivetta","doi":"10.1080/10428194.2026.2727810","DOIUrl":"https://doi.org/10.1080/10428194.2026.2727810","url":null,"abstract":"Lung ultrasound (LUS) is a reliable tool for diagnosing pneumonia, a common complication in onco-hematological patients; however, data in this setting are limited. We assessed the diagnostic accuracy and clinical usefulness of LUS performed by trained hematologists in febrile neutropenic patients, compared to chest X-ray (CXR), and using high-resolution computed tomography (HRCT) as reference test. At fever onset, 123 hospitalized neutropenic onco-hematological patients underwent a bedside CXR and LUS. Seventy-one patients underwent HRCT for a positive CXR, persistent fever or respiratory failure, and were included in the analysis. Overall, 39 patients developed pneumonia. Compared to HRCT, LUS and CXR showed a sensitivity of 71.8% and 51.3%, and a specificity of 87.5% and 81.3%, respectively. AUC-ROC was 0.80 for LUS and 0.66 for CXR (p = 0.04). Net reclassification index (NRI) of LUS was 20.5% for pneumonia, and 6.3% for no pneumonia cases. LUS showed high diagnostic accuracy for pneumonia in this setting.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149025388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the editor regarding 'Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan'. 致编辑关于“急性髓性白血病患者的真实世界维托克拉克斯剂量模式和治疗持久性：日本社区药房数据库研究”的信。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-16 DOI: 10.1080/10428194.2026.2732486

Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, Silvia Cornejo-Uixeda

引用次数: 0

Prognostic factors and survival in HHV8 positive diffuse large B cell lymphoma: a national cancer database analysis. HHV8阳性弥漫性大B细胞淋巴瘤的预后因素和生存率：一项国家癌症数据库分析

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-16 DOI: 10.1080/10428194.2026.2728612

Gaelle C Haddad, You Li, Liang Hong, Chieh-Lin Fu, Yehuda Galili, Chakra P Chaulagain

{"title":"Prognostic factors and survival in HHV8 positive diffuse large B cell lymphoma: a national cancer database analysis.","authors":"Gaelle C Haddad, You Li, Liang Hong, Chieh-Lin Fu, Yehuda Galili, Chakra P Chaulagain","doi":"10.1080/10428194.2026.2728612","DOIUrl":"https://doi.org/10.1080/10428194.2026.2728612","url":null,"abstract":"HHV8-positive diffuse large B-cell lymphoma (HHV8+ DLBCL) is a rare and aggressive lymphoma frequently associated with multicentric Castleman disease. Population-based data remain limited. Using the National Cancer Database (2004-2023), we analyzed 262 patients with histologically confirmed HHV8+ DLBCL (ICD-O-3 9738/3), representing the largest cohort to date. The cohort was predominantly male (76.7%), White (66.0%), with a mean age of 52.6 years. The primary site was nodal in 78.6%. Systemic therapy was administered in 72.9% of patients. Median overall survival was 133 months, with 1-, 3-, and 5-year survival rates of 68.2%, 63.1%, and 59.9%, respectively. On multivariable Cox regression, age ≥60 years, Charlson-Deyo score ≥1, HIV-positive status, and lack of systemic therapy and surgery to the primary site were independently associated with worse overall survival. In a subgroup analysis restricted to patients with known HIV status (n = 113), HIV-positive status was the only variable significantly associated with worse overall survival on univariable analysis.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the gut: cutaneous manifestations and transformation in indolent T-cell lymphoma of the gastrointestinal tract. 肠道外：胃肠道惰性t细胞淋巴瘤的皮肤表现和转化。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-16 DOI: 10.1080/10428194.2026.2732620

Toan S Bui, Jeffrey D Weiner, Olivia Pierog, Jaroslaw Jedrych, Cole Sterling, Sima Rozati

引用次数: 0

Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML)-a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US. 慢性髓性白血病（CML）患者的不良事件、生活质量和工作损害——美国一线和二线酪氨酸激酶抑制剂（TKI）不耐受的调查

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-13 DOI: 10.1080/10428194.2026.2721033

Kelly Schoenbeck, David Wei, Nisha C Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guérin, Joan Clements, Karen DeMairo, Jennifer Hiller, Kathryn E Flynn

{"title":"Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML)-a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US.","authors":"Kelly Schoenbeck, David Wei, Nisha C Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guérin, Joan Clements, Karen DeMairo, Jennifer Hiller, Kathryn E Flynn","doi":"10.1080/10428194.2026.2721033","DOIUrl":"https://doi.org/10.1080/10428194.2026.2721033","url":null,"abstract":"Tyrosine kinase inhibitors (TKIs) improve survival for people with chronic myeloid leukemia (CML) but may cause adverse events (AEs) that impair quality of life (QoL). Adults with CML receiving first- or second-line TKI therapy in the United States (US) completed validated questionnaires to assess AEs (PRO-CTCAE), QoL (PROMIS Global Physical Health [GPH] and Global Mental Health [GMH]), and work productivity and activity impairment (WPAI:SHP). Of 271 participants, 76.4% experienced ≥1 AE (median 3 [range 0-14]), with the most common being fatigue (53.9%), pain (44.3%), and gastrointestinal symptoms (36.9%). Mean (SD) GPH and GMH T-scores were worse than general population averages (50) at 42.6 (7.0) and 44.4 (7.7), respectively. Mean (SD) activity impairment was 37.3% (24.6). Chronic AEs were associated with worse GPH/GMH T-scores and activity impairment (p < 0.05). The findings demonstrate the relationship between TKI-related AEs and QoL for US patients and the need for improved management strategies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding access to leukemia specialists in the venetoclax era. 在venetoclax时代扩大白血病专家的机会。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-13 DOI: 10.1080/10428194.2026.2731270

Michael Daunov

引用次数: 0